Genetic Signatures Ltd posted a AUD 3.1 million revenue shortfall in the second half of fiscal 2026, falling 54% below analyst forecasts of AUD 6.7 million. The Australian molecular diagnostics company reported total revenue of AUD 14.8 million for the year ended June 30, 2026, a 7% decline from the prior year.
The company narrowed its annual net loss to AUD 14 million, a 30% improvement from the prior year’s AUD 20 million deficit. Operating cash outflow also improved by 37%, declining to AUD 7 million from AUD 12.3 million in the previous period. Genetic Signatures maintained a cash balance of AUD 22.1 million at financial year-end, though this edged down to AUD 21.3 million by August 25, 2026.
Employee expenses fell 16% year-over-year, while the company expects annual cost savings of approximately AUD 5 million in fiscal 2027. Gross profit margin remained stable at around 51%, and the current ratio stood at 8.99. Management highlighted a delayed and muted flu season in Australia, which contributed to a 73% drop in positive flu cases compared to the prior year, reducing testing volumes.
The company’s stock rose 3.75% in pre-market trading to AUD 0.083, following a 35.6% weekly gain, though it remains down 68% year-to-date. The shares trade below InvestingPro’s fair value estimate of AUD 0.06. The 52-week range spans from AUD 0.051 to AUD 0.43.
Genetic Signatures paused a customized instrumentation development program and shifted focus to off-the-shelf robotics solutions. Expansion in the U.S. has been paused to reassess market access, though the company continues to operate three active sites. Management confirmed ongoing discussions with Microba regarding a potential corporate transaction, citing potential overhead savings and overlapping enteric diagnostics businesses, while stating no discussions with BCAL Diagnostics.
The company implemented an AI policy, which management said improved productivity and regulatory efficiency. First product launches are expected in early 2027, with a second product slated for later in the year. The company’s growth opportunities are focused on the next 12 to 18 months.
